MET overexpression

News alerts, weekly reports and conference planners

Entrez ID:

4233

Related biomarkers:

‹

›

MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3
MET overexpression	Melanoma	MET overexpression	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
MET overexpression	Colorectal Cancer	MET overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
MET overexpression	Glioblastoma	MET overexpression	Glioblastoma	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	savolitinib Sensitive: C3 – Early Trials savolitinib Sensitive : C3	savolitinib Sensitive: C3 – Early Trials savolitinib Sensitive : C3
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3
MET overexpression	Squamous Cell Carcinoma of Head and Neck	MET overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	cetuximab Resistant: C4 – Case Studies cetuximab Resistant : C4	cetuximab Resistant: C4 – Case Studies cetuximab Resistant : C4
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	trametinib + dabrafenib Resistant: C4 – Case Studies trametinib + dabrafenib Resistant : C4	trametinib + dabrafenib Resistant: C4 – Case Studies trametinib + dabrafenib Resistant : C4
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D
MET overexpression	Adrenal Cortex Carcinoma	MET overexpression	Adrenal Cortex Carcinoma	cabozantinib capsule Sensitive: D – Preclinical cabozantinib capsule Sensitive : D	cabozantinib capsule Sensitive: D – Preclinical cabozantinib capsule Sensitive : D
MET overexpression	Lung Adenocarcinoma	MET overexpression	Lung Adenocarcinoma	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
MET overexpression	Melanoma	MET overexpression	Melanoma	BRAF inhibitor + MEK inhibitor Resistant: D – Preclinical BRAF inhibitor + MEK inhibitor Resistant : D	BRAF inhibitor + MEK inhibitor Resistant: D – Preclinical BRAF inhibitor + MEK inhibitor Resistant : D
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	WXSH0011 Sensitive: D – Preclinical WXSH0011 Sensitive : D	WXSH0011 Sensitive: D – Preclinical WXSH0011 Sensitive : D
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	crizotinib + chidamide Sensitive: D – Preclinical crizotinib + chidamide Sensitive : D	crizotinib + chidamide Sensitive: D – Preclinical crizotinib + chidamide Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MG132 Sensitive: D – Preclinical MG132 Sensitive : D	MG132 Sensitive: D – Preclinical MG132 Sensitive : D
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	WXSH0011 Sensitive: D – Preclinical WXSH0011 Sensitive : D	WXSH0011 Sensitive: D – Preclinical WXSH0011 Sensitive : D
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	S95027 Sensitive: D – Preclinical S95027 Sensitive : D	S95027 Sensitive: D – Preclinical S95027 Sensitive : D
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D

MET overexpression

Associations